NCT04691349 - CAR-T for r/r Malignant Tumors in Children | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 27, 2020

Primary Completion Date

January 26, 2021

Study Completion Date

September 26, 2021

Conditions

CAR-TChild, OnlyMalignant Tumor

Interventions

DRUG

CAR-T

The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region.

Trial Locations (1)

215000

RECRUITING

Chilren's Hospital of Soochow University, Suzhou